2008
DOI: 10.1378/chest.07-2048
|View full text |Cite
|
Sign up to set email alerts
|

Sputum Eosinophils and the Response of Exercise-Induced Bronchoconstriction to Corticosteroid in Asthma

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

1
65
0
3

Year Published

2010
2010
2019
2019

Publication Types

Select...
7
2
1

Relationship

0
10

Authors

Journals

citations
Cited by 90 publications
(69 citation statements)
references
References 22 publications
1
65
0
3
Order By: Relevance
“…Phenotyping of asthma with inflammometry, especially with the use of sputum cytology (6), might offer advantages such as predicting treatment responses (7,8), highlighting mechanistic pathways involved in disease pathogenesis (9), and predicting future risk (10). Investigations of granulocyte infiltration in induced sputum suggested eosinophilic, neutrophilic, mixed granulocytic, and paucigranulocytic phenotypes.…”
mentioning
confidence: 99%
“…Phenotyping of asthma with inflammometry, especially with the use of sputum cytology (6), might offer advantages such as predicting treatment responses (7,8), highlighting mechanistic pathways involved in disease pathogenesis (9), and predicting future risk (10). Investigations of granulocyte infiltration in induced sputum suggested eosinophilic, neutrophilic, mixed granulocytic, and paucigranulocytic phenotypes.…”
mentioning
confidence: 99%
“…30 In addition, the results of several studies suggest that the presence and severity of EIB is significantly associated with the number of eosinophils measured from the blood and sputum of subjects with asthma. [31][32][33][34] Therefore, we hypothesized that eosinophils contribute to the mechanisms underlying EIB and the therapeutic effects of LTRA therapy, and then we investigated the effects of polymorphism combinations on LTRA drug responsiveness and on TEC in children with asthma. Interestingly, we found that the presence of the PTGDR À441C and LTC4S À444C alleles appeared to be associated with increased TEC in children with asthma, especially children with atopic asthma.…”
Section: Discussionmentioning
confidence: 99%
“…What is not known is how long the benefit of the ICS treatment lasts following cessation of ICS treatment. If the benefit of ICSs against EIB is a reduction in the number of inflammatory cells, for example eosinophils and mast cells, then the benefit should last until these cells return in significant numbers with adequate concentrations of mediators [17,18]. This timing will depend on the subject's exposure to relevant allergens, viruses and other exacerbating factors.…”
Section: Editorialmentioning
confidence: 99%